Skip to main content

Advertisement

Table 1 Summary of the included studies

From: Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis

No Author (Year) Country Type of study Age (range) Sample Size (all) Patients/control (n) Cutoff (ng mL-l) Sample Inclusion criteria Exclusion References Assay
1 Tanır Basaranoglu 2018 Turkey Prospective 1mo–18 y 138 58 sepsis/80 (healthy controls) 990 serum 1 mo–18 y, clinical signs of CRBSI received antibiotics within the 24 h of presentation with fever 2009 IDSA guideline ELISA
2 Baraka 2018 Egypt Case-control 2–15 y 60 18 sepsis/42 (non-sepsis patients) 1014 plasma <  16 y, pediatric patients with HM, during episodes of fever and neutropenia after receiving CTx age > 16 y, non-HM pediatric patients, not on chemotherapy blood culture PATHFAST
3 Plesko 2016–1 Slovakia Prospective 1.5–18.9 y 55 12 sepsis/43 (non-sepsis patients) 240 unspecified <  18.9 y, pediatric patients with HM, the presence of fever, hypothermia, chills, or another sign of possible sepsis Febrile episodes thought to be an adverse effect of CTx, not having blood culture drawn, patients with proven non-bacterial infection blood culture PATHFAST
3 Plesko 2016–2 Slovakia Prospective 1.5–18.9 y 55 13 sepsis/42 (non-sepsis patients) 299 unspecified <  18.9 y, pediatric patients with HM, the presence of fever, hypothermia, chills, or another sign of possible sepsis Febrile episodes thought to be an adverse effect of CTx, not having blood culture drawn, patients with proven non-bacterial infection modified IPSCC definition (2005) PATHFAST
  1. CRBSI catheter-related blood stream infection, CTx chemotherapy, HM hematologic malignancy, IDSA Infectious Diseases Society of America, IPSCC International Pediatric Sepsis Consensus Conference